Loading…
Loading…
EVLO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EVLO and 80,000+ other tickers.
See exactly how EVLO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EVLO and 80,000+ other tickers.
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational…
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 1,885 put options on the stock. This represents an increase of 1,101% compared to the average volume of 157 put options. Evelo Biosciences Stock Performance Evelo Biosciences has a 1 year low of $0.00 and
Profitability This table compares Silverback Therapeutics and Evelo Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Evelo Biosciences N/A N/A N/A Valuation and Earnings This table compares Silverback Therapeutics and Evelo Biosciences"s top-line revenue, earnings per share (EPS) and valuation.
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 1,885 put options on the company. This represents an increase of approximately 1,101% compared to the typical daily volume of 157 put options. Evelo Biosciences Stock Down 50.0% Evelo Biosciences stock opened at $0.00
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 1,885 put options on the stock. This is an increase of 1,101% compared to the average daily volume of 157 put options. Evelo Biosciences Trading Down 80.0% NASDAQ: EVLO opened at $0.00 on Thursday. The company
Insider and Institutional Ownership 44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and